GlassScriptPhysician profile
Erika Bennett
NPI 1295388379
$4,730.22
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $345 · 2022: $704 · 2023: $3,540 · 2024: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,899 · Travel and Lodging: $1,562 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,898.60 |
| Travel and Lodging | $1,562.36 |
| Education | $220.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,976.24 | 2022-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Medtronic, INC. | $1,842.83 | 2022-2023 | Corevalve Evolut R |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $407.41 | 2021-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $135.86 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $107.15 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $55.89 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $54.65 | 2021-2023 | Eliquis |
| Esperion Therapeutics, INC. | $39.00 | 2021-2022 | |
| Pfizer INC. | $38.98 | 2021-2022 | |
| Glaxosmithkline, LLC. | $22.49 | 2023 | Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $19.93 | 2024 | Eohilia |
| Csl Behring | $15.33 | 2024 | Kcentra |
| Getinge USA Sales, LLC | $14.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.